

APPLICANT(S): RUBINSTEIN, Abraham et al.
SERIAL NO.: 10/630,917
FILED: July 31, 2003
Page 2

AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1. *(Previously Presented)* A synchronous drug delivery composition comprising an erodable, hydrogel-forming polymeric matrix which comprises:

- a) a blend which comprises a hydrophilic polymeric cellulose derivative and a hydrophobic polymeric methacrylic acid derivative;
- b) a drug;
- c) an agent which enhances intestinal drug absorption; and
- d) an agent which inhibits intestinal drug degradation,

wherein erosion of said erodable matrix, permits synchronous release of said drug, said agent which enhances intestinal drug absorption and said agent which inhibits intestinal drug degradation.

2-4 *(Cancelled)*

5. *(Previously Presented)* A pharmaceutical composition comprising the synchronous drug delivery composition of claim 1 and a carrier or diluent.

6. *(Previously Presented)* A pharmaceutical composition comprising the synchronous drug delivery composition of claim 28 and a carrier or diluent.

7. *(Previously Presented)* A pharmaceutical composition comprising the synchronous drug delivery composition of claim 29 and a carrier or diluent.

8. *(Cancelled)*

9. *(Previously Presented)* A drug delivery composition according to claim 1, wherein the composition is in the form of a plain matrix tablet.

10. *(Previously Presented)* A drug delivery composition according to claim 28, wherein the composition is in the form of a plain matrix tablet.

11. *(Previously Presented)* A drug delivery composition according to claim 29, wherein the composition is in the form of a plain matrix tablet.

APPLICANT(S): RUBINSTEIN, Abraham et al.
SERIAL NO.: 10/630,917
FILED: July 31, 2003
Page 3

12-16 (*Cancelled*)

17 (*Previously Presented*) A drug delivery composition according to claim 1, wherein the composition is coated with an enterocoating.

18. (*Previously Presented*) A drug delivery composition according to claim 28, wherein the composition is coated with an enterocoating.

19. (*Previously Presented*) A drug delivery composition according to claim 29, wherein the composition is coated with an enterocoating.

20-22 (*Cancelled*)

23. (*Previously Presented*) A method of synchronically releasing a drug, an agent which inhibits intestinal drug degradation and an agent which enhances intestinal drug absorption, comprising the step of administering the composition of claim 1.

24. (*Previously Presented*) A method of increasing the bioavailability of a drug, comprising the step of administering the drug delivery composition according to claim 1.

25. (*Previously Presented*) A method of increasing the bioavailability of a drug, comprising the step of administering the drug delivery composition according to claim 28.

26. (*Previously Presented*) A method of increasing the bioavailability of a drug, comprising the step of administering the drug delivery composition according to claim 29.

27. (*Cancelled*)

28. (*Previously Presented*) A drug delivery composition according to claim 1, wherein said cellulose derivative is hydroxypropylmethyl cellulose, methylcellulose, carboxymethyl cellulose or hydroxypropyl cellulose.

29. (*Currently amended*) A drug delivery composition according to claim 1, wherein said methacrylic acid derivative is Eudragit® RL a dimethylaminoethylacrylate/ethylmethacrylate copolymer, a copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the neutral (meth)acrylic acid esters is 1:20.